Englewood Lab Inc (950140) - Total Liabilities
Based on the latest financial reports, Englewood Lab Inc (950140) has total liabilities worth ₩75.21 Billion KRW (≈ $50.97 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Englewood Lab Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Englewood Lab Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Englewood Lab Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Englewood Lab Inc (950140) total assets.
Englewood Lab Inc Competitors by Total Liabilities
The table below lists competitors of Englewood Lab Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Calitech Co Ltd
TWO:6532
|
Taiwan | NT$294.20 Million |
|
Pollux Investasi Internasional Tbk PT
JK:POLI
|
Indonesia | Rp2.14 Trillion |
|
China Silver Group Limited
F:2CS
|
Germany | €530.85 Million |
|
Tera Autotech
TWO:6234
|
Taiwan | NT$1.39 Billion |
|
QRF SCA
BR:QRF
|
Belgium | €128.00 Million |
|
Black Diamond Therapeutics Inc
NASDAQ:BDTX
|
USA | $28.94 Million |
|
Payton -L
TA:PAYT
|
Israel | ILA10.09 Million |
|
Affluent Medical SAS
PA:AFME
|
France | €38.73 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Englewood Lab Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Englewood Lab Inc net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Englewood Lab Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Englewood Lab Inc (2015–2024)
The table below shows the annual total liabilities of Englewood Lab Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩37.98 Million ≈ $25.74K |
-16.60% |
| 2023-12-31 | ₩45.54 Million ≈ $30.86K |
+36.28% |
| 2022-12-31 | ₩33.42 Million ≈ $22.65K |
-16.12% |
| 2021-12-31 | ₩39.84 Million ≈ $27.00K |
-9.79% |
| 2020-12-31 | ₩44.16 Million ≈ $29.93K |
-5.69% |
| 2019-12-31 | ₩46.83 Million ≈ $31.74K |
+8.93% |
| 2018-12-31 | ₩42.99 Million ≈ $29.13K |
+43.42% |
| 2017-12-31 | ₩29.98 Million ≈ $20.31K |
+275.36% |
| 2016-12-31 | ₩7.99 Million ≈ $5.41K |
-99.96% |
| 2015-12-31 | ₩19.56 Billion ≈ $13.25 Million |
-- |
About Englewood Lab Inc
Englewood Lab, Inc. engages in the research, development, manufacture, and sale of cosmetic products in the United States, Korea, Canada, China, Japan Europe, and internationally. It offers masks, cleansers, and anti-aging skincare products, as well as face, eye, and body moisturizer; primers and foundations, BB and CC Cream, concealer, blush and illuminizers, bronzer highlighter, and lip care; a… Read more